Subclinical carotid atherosclerosis and cardiovascular risk factors in HIV-infected patients

Wiesława Kwiatkowska1, Brygida Knysz, Justyna Drelichowska-Durawa

  • 1Department of Angiology, Regional Specialist Hospital in Wroclaw, Research and Development Center, Poland. kwiatkowska_w@interia.pl

Insights

HIV patients on antiretroviral therapy have increased cardiovascular disease risk due to more advanced subclinical atherosclerosis. Key factors influencing carotid intima-media thickness (cIMT) include age, hypertension, cholesterol, and ARV treatment duration.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Public Health

Background:

  • HIV infection and antiretroviral (ARV) drug use are associated with elevated cardiovascular disease (CVD) risk.
  • Subclinical atherosclerosis, a precursor to CVD, requires further investigation in HIV-positive individuals.

Purpose of the Study:

  • To assess carotid artery subclinical atherosclerosis progression (carotid intima-media thickness [cIMT] and plaque incidence) in HIV patients.
  • To analyze the relationship between cIMT and cardiovascular disease risk factors within this cohort.

Main Methods:

  • Comparative analysis of 72 HIV-infected patients and 27 HIV-negative controls, matched for age and sex.
  • Data collection included HIV/ARV status, cardiovascular risk factors, and carotid artery ultrasound (cIMT, plaque assessment).

Main Results:

  • HIV patients exhibited more advanced carotid atherosclerosis (higher cIMT and plaque incidence).
  • Significant differences in cardiovascular risk profiles were observed, including lower BMI, higher WHR, altered lipid profiles (lower cholesterol, higher triglycerides), and increased smoking prevalence.
  • cIMT strongly correlated with age, hypertension, non-high-density lipoprotein (non-HDL) cholesterol, and ARV duration. Total cholesterol, LDL cholesterol, and lifetime smoking also impacted cIMT.

Conclusions:

  • HIV-infected individuals, particularly those on ARV therapy, display accelerated subclinical atherosclerosis.
  • Cardiovascular risk factor management and monitoring are crucial in HIV patients to mitigate atherosclerosis progression.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...